BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 36649695)

  • 21. TRPS1 expression in primary and metastatic prostatic adenocarcinoma, muscle invasive bladder urothelial carcinoma, and breast carcinoma: Is TRPS1 truly specific and sensitive for a breast primary?
    Bachert SE; Di J; Zhang S; Short HE; Piecoro DW; McDonald RJ; Myint ZW; Hensley PJ; Allison DB
    Hum Pathol; 2024 Jan; 143():42-49. PubMed ID: 38052269
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer.
    Ai D; Yao J; Yang F; Huo L; Chen H; Lu W; Soto LMS; Jiang M; Raso MG; Wang S; Bell D; Liu J; Wang H; Tan D; Torres-Cabala C; Gan Q; Wu Y; Albarracin C; Hung MC; Meric-Bernstam F; Wistuba II; Prieto VG; Sahin AA; Ding Q
    Mod Pathol; 2021 Apr; 34(4):710-719. PubMed ID: 33011748
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Utility of uroplakin II expression as a marker of urothelial carcinoma.
    Tian W; Guner G; Miyamoto H; Cimino-Mathews A; Gonzalez-Roibon N; Argani P; Li X; Sharma R; Subhawong AP; Rezaei K; Bivalacqua TJ; Epstein JI; Bishop JA; Netto GJ
    Hum Pathol; 2015 Jan; 46(1):58-64. PubMed ID: 25449628
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytokeratin 5 and cytokeratin 6 expressions are unconnected in normal and cancerous tissues and have separate diagnostic implications.
    Völkel C; De Wispelaere N; Weidemann S; Gorbokon N; Lennartz M; Luebke AM; Hube-Magg C; Kluth M; Fraune C; Möller K; Bernreuther C; Lebok P; Clauditz TS; Jacobsen F; Sauter G; Uhlig R; Wilczak W; Steurer S; Minner S; Krech RH; Dum D; Krech T; Marx AH; Simon R; Burandt E; Menz A
    Virchows Arch; 2022 Feb; 480(2):433-447. PubMed ID: 34559291
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterisation of GATA3 expression in invasive breast cancer: differences in histological subtypes and immunohistochemically defined molecular subtypes.
    Shaoxian T; Baohua Y; Xiaoli X; Yufan C; Xiaoyu T; Hongfen L; Rui B; Xiangjie S; Ruohong S; Wentao Y
    J Clin Pathol; 2017 Nov; 70(11):926-934. PubMed ID: 28428285
    [TBL] [Abstract][Full Text] [Related]  

  • 26. GATA3 expression in clear cell adenocarcinoma of the lower urinary tract: a potential diagnostic pitfall.
    Akgul M; Humble R; Osme A; Yuce S; Kocak EN; Najafzadeh P; Sangoi A; Pattnaik N; Mishra S; Sharma S; Shaker N; Kaushal S; Baisakh M; Lightle AR; Balzer BL; Xiao GQ; MacLennan GT; Osunkoya AO; Parwani A; Cheng L; Bellizzi A; Mohanty SK
    Diagn Pathol; 2022 Nov; 17(1):87. PubMed ID: 36320040
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray.
    Higgins JP; Kaygusuz G; Wang L; Montgomery K; Mason V; Zhu SX; Marinelli RJ; Presti JC; van de Rijn M; Brooks JD
    Am J Surg Pathol; 2007 May; 31(5):673-80. PubMed ID: 17460449
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnostic and Prognostic Roles of GATA3 Immunohistochemistry in Urothelial Carcinoma.
    Yoo D; Min KW; Pyo JS; Kim NY
    Medicina (Kaunas); 2023 Aug; 59(8):. PubMed ID: 37629741
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trophoblast Cell Surface Antigen 2 Expression in Human Tumors: A Tissue Microarray Study on 18,563 Tumors.
    Dum D; Taherpour N; Menz A; Höflmayer D; Völkel C; Hinsch A; Gorbokon N; Lennartz M; Hube-Magg C; Fraune C; Bernreuther C; Lebok P; Clauditz TS; Jacobsen F; Sauter G; Uhlig R; Wilczak W; Steurer S; Minner S; Marx AH; Simon R; Burandt E; Krech T; Luebke AM
    Pathobiology; 2022; 89(4):245-258. PubMed ID: 35477165
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic utility of GATA3 immunohistochemical expression in urothelial carcinoma.
    Agarwal H; Babu S; Rana C; Kumar M; Singhai A; Shankhwar SN; Singh V; Sinha RJ
    Indian J Pathol Microbiol; 2019; 62(2):244-250. PubMed ID: 30971548
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunohistological expression of oestrogen receptor, progesterone receptor, mammaglobin, human epidermal growth factor receptor 2 and GATA-binding protein 3 in non-small-cell lung cancer.
    Kriegsmann K; Zgorzelski C; Muley T; Christopoulos P; von Winterfeld M; Herpel E; Goeppert B; Mechtersheimer G; Sinn P; Stenzinger A; Schirmacher P; Winter H; Eichinger M; Warth A; Kriegsmann M
    Histopathology; 2020 Dec; 77(6):900-914. PubMed ID: 32634256
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of androgen receptor and GATA binding protein 3 as immunohistochemical markers in the diagnosis of metastatic breast carcinoma to the lung.
    Hattori Y; Yoshida A; Yoshida M; Takahashi M; Tsuta K
    Pathol Int; 2015 Jun; 65(6):286-92. PubMed ID: 25727644
    [TBL] [Abstract][Full Text] [Related]  

  • 33. GATA3 positivity is associated with poor prognosis in patients with oesophageal squamous cell carcinoma.
    Chi Z; Balani J; Gopal P; Hammer S; Xu J; Peng L
    J Clin Pathol; 2023 Jul; 76(7):474-479. PubMed ID: 35039449
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comprehensive analysis of GATA3 expression in carcinomas of various origins with emphasis on lung carcinomas.
    Bota EC; Koumoundourou D; Ravazoula P; Zolota V; Psachoulia C; Kardari M; Karampitsakos T; Tzouvelekis A; Tzelepi V; Sampsonas F
    Monaldi Arch Chest Dis; 2023 Aug; ():. PubMed ID: 37667882
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pan-keratin Immunostaining in Human Tumors: A Tissue Microarray Study of 15,940 Tumors.
    Menz A; Gorbokon N; Viehweger F; Lennartz M; Hube-Magg C; Hornsteiner L; Kluth M; Völkel C; Luebke AM; Fraune C; Uhlig R; Minner S; Dum D; Höflmayer D; Sauter G; Simon R; Burandt E; Clauditz TS; Lebok P; Jacobsen F; Steurer S; Krech T; Marx AH; Bernreuther C
    Int J Surg Pathol; 2023 Sep; 31(6):927-938. PubMed ID: 35946088
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trichorhinophalangeal syndrome type 1 (TRPS1) expression in male breast carcinoma.
    Law T; Piotrowski MJ; Ning J; Jiang X; Ding Q; Sahin AA
    Hum Pathol; 2023 Aug; 138():62-67. PubMed ID: 37331526
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of bladder cancer subtypes in neurogenic bladder tumors.
    Manach Q; Cussenot O; Rouprêt M; Gamé X; Chartier-Kastler E; Reus C; Camparo P; Compérat E; Phé V
    Can J Urol; 2018 Feb; 25(1):9161-9167. PubMed ID: 29524970
    [TBL] [Abstract][Full Text] [Related]  

  • 38. GATA3: a promising marker for metastatic breast carcinoma in serous effusion specimens.
    Shield PW; Papadimos DJ; Walsh MD
    Cancer Cytopathol; 2014 Apr; 122(4):307-12. PubMed ID: 24421220
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Young investigator challenge: The utility of GATA3 immunohistochemistry in the evaluation of metastatic breast carcinomas in malignant effusions.
    Lew M; Pang JC; Jing X; Fields KL; Roh MH
    Cancer Cytopathol; 2015 Oct; 123(10):576-81. PubMed ID: 26465236
    [TBL] [Abstract][Full Text] [Related]  

  • 40. GATA3 expression in sarcomatoid urothelial carcinoma of the bladder.
    Fatima N; Osunkoya AO
    Hum Pathol; 2014 Aug; 45(8):1625-9. PubMed ID: 24824028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.